Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) announced its earnings results on Monday. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01, Zacks reports.
Cardiol Therapeutics Price Performance
Shares of CRDL traded up $0.01 on Monday, reaching $0.97. The stock had a trading volume of 140,556 shares, compared to its average volume of 386,192. Cardiol Therapeutics has a twelve month low of $0.88 and a twelve month high of $3.12. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average of $1.21 and a 200 day moving average of $1.53. The firm has a market capitalization of $80.11 million, a PE ratio of -2.49 and a beta of 0.95.
Wall Street Analyst Weigh In
CRDL has been the topic of several analyst reports. RODMAN&RENSHAW upgraded Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 28th. Rodman & Renshaw began coverage on shares of Cardiol Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research note on Monday, February 24th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $8.40.
About Cardiol Therapeutics
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
- Five stocks we like better than Cardiol Therapeutics
- Profitably Trade Stocks at 52-Week Highs
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Investing In Preferred Stock vs. Common Stock
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- High Flyers: 3 Natural Gas Stocks for March 2022
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
